Acta Neuropathologica

, Volume 115, Issue 2, pp 261–262 | Cite as

MGMT immunoexpression predicts responsiveness of pituitary tumors to temozolomide therapy

  • Kalman Kovacs
  • Bernd W. ScheithauerEmail author
  • Matilde Lombardero
  • Roger E. McLendon
  • Luis V. Syro
  • Humberto Uribe
  • Leon D. Ortiz
  • Luis C. Penagos


Pituitary Adenoma Temozolomide Pituitary Tumor Tetrazine MGMT Expression 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



Authors are grateful to the Jarislowsky and the Lloyd Carr Harris Foundations.


  1. 1.
    Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Pepin SE, Simmons NE (2004) Pituitary carcinomas respond to temozolomide. Neurooncol 6:374Google Scholar
  2. 2.
    Fadul CE, Kominsky AL, Meyer LP, Kingman LS, Kinlaw WB, Rhodes CH, Eskey CJ, Simmons NE (2006) Long-term response of pituitary carcinoma to temozolomide. Report of two cases. J Neurosurg 105:621–626PubMedGoogle Scholar
  3. 3.
    Friedman HS, McLendon RE, Kerby T, Dugan M, Bigner SH, Henry AJ, Ashley DM, Krischer J, Lovell S, Rasheed K, Marchev F, Seman AJ, Cokgor I, Rich J, Stewart E, Colvin OM, Provenzale JM, Bigner DD, Haglund MM, Friedman AH, Modrich PL (1998) DNA mismatch repair and O6-alkylguanine-DNA alkyltransferase analysis and response to Temodal in newly diagnosed malignant glioma. J Clin Oncol 16:3851–3857PubMedGoogle Scholar
  4. 4.
    Kovacs K, Horvath E, Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE (2007) Temozolomide therapy in a man with an aggressive prolactin-secreting pituitary neoplasm: morphological findings. Hum Pathol 38:185–189PubMedCrossRefGoogle Scholar
  5. 5.
    Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS (2006) Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 24:401–406PubMedCrossRefGoogle Scholar
  6. 6.
    Levin N, Lavon I, Zelikovitsh B, Fuchs D, Bokstein F, Fellig Y, Siegal T (2006) Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer 106:1759–1765PubMedCrossRefGoogle Scholar
  7. 7.
    Lim S, Shahinian H, Maya MM, Yong W, Heaney AP (2006) Temozolomide: a novel treatment for pituitary carcinoma. Lancet Oncol 7:518–520PubMedCrossRefGoogle Scholar
  8. 8.
    McLendon RE, Cleveland L, Pegram C, Bigner SH, Bigner DD, Friedman HS (1998) Immunohistochemical detection of the DNA repair enzyme O6-methylguanine-DNA methyltransferase in formalin-fixed, paraffin-embedded astrocytomas. Lab Invest 78:643–644PubMedGoogle Scholar
  9. 9.
    Mollemann M, Wolter M, Felsberg J, Collins VP, Reifenberger G (2005) Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors. Int J Cancer 113:379–385PubMedCrossRefGoogle Scholar
  10. 10.
    Neff LM, Weil M, Cole A, Hedges TR, Shucart W, Lawrence D, Zhu JJ, Tischler AS, Lechan RM (2007) Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists. Pituitary 10:81–86PubMedCrossRefGoogle Scholar
  11. 11.
    Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431–3437PubMedCrossRefGoogle Scholar
  12. 12.
    Stupp R, Gander M, Leyvraz S, Newlands E (2001) Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2:552–560PubMedCrossRefGoogle Scholar
  13. 13.
    Syro LV, Uribe H, Penagos LC, Ortiz LD, Fadul CE, Horvath E, Kovacs K (2006) Antitumour effects of temozolomide in a man with a large, invasive prolactin-producing pituitary neoplasm. Clin Endocrinol (Oxf) 65:552–553CrossRefGoogle Scholar
  14. 14.
    Zhu Y, Shaninian H, Hakimian B, Bonert V, Lim S, Heaney A (2004) Temodar: novel treatment for pituitary carcinoma (Abstract). US Endocr Soc 138:43–45Google Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Kalman Kovacs
    • 1
  • Bernd W. Scheithauer
    • 2
    Email author
  • Matilde Lombardero
    • 3
  • Roger E. McLendon
    • 4
  • Luis V. Syro
    • 5
  • Humberto Uribe
    • 6
  • Leon D. Ortiz
    • 7
  • Luis C. Penagos
    • 8
  1. 1.Department of Pathology, St. Michael’s HospitalUniversity of TorontoTorontoCanada
  2. 2.Department of PathologyMayo ClinicRochesterUSA
  3. 3.Department of Anatomy, Veterinary SciencesUniversity of Santiago de CompostelaLugoSpain
  4. 4.Department of PathologyDuke University Medical CenterDurhamUSA
  5. 5.Department of NeurosurgeryHospital Pablo Tobon UribeMedellinColombia
  6. 6.Department of NeurosurgeryClinica MedellinMedellinColombia
  7. 7.Department of NeurosurgeryInstituto de CancerologíaMedellinColombia
  8. 8.Department of OtolaryngologyClinica MedellinMedellinColombia

Personalised recommendations